Global Atrophic Vaginitis Treatment Market is Expanding Owing to Growing Prevalence of Postmenopausal Vaginal Atrophy and Rising Healthcare Plans
Atrophic Vaginitis Treatment Market |
Overview:
Atrophic vaginitis is a skin condition of the vulva and vagina that happens when there is not enough estrogen in the body. It can happen to any woman. It is most common in perimenopausal and postmenopausal women. Estrogen keeps the vulva thick and the skin moist. It also prevents certain infections that occur in the genital area. The symptoms of atrophic vaginitis include vaginal dryness and itching, burning, pain with sexual activity, more frequent or urgent urination, and the feeling that you have to urinate right away. Lowering estrogen levels also decreases the lining of the vulva and vagina, which can make it harder to suck in air during sexual intercourse or coughing or sneezing. It can lead to a change in the acidity of the vagina and a loss of natural lubrication. Atrophic vaginitis also increases the risk of urinary tract problems such as bladder and urethra infections.
Market Dynamics:
Increasing product launches is estimated to augment growth of the global atrophic vaginitis treatment market during the forecast period. For instance, Upsher-Smith Laboratories, LLC, declared the launch of three novel products USP Fluvoxamine Maleate Tablets, Clonidine Hydrochloride Extended-release Tablets, and Haloperidol Tablets in 2020. These products will expand the company’s generic portfolio. Moreover, lack of awareness regarding the infection and growing adverse effects of vaginal gels is anticipated to restrain growth of the global atrophic vaginitis treatment market during the forecast period.
Impact of COVID-19:
The pandemic resulted in causing disturbances in supply chains and also affecting the demand and production of various products. As manufacturing activities were halted, demand for several products has decreased. This led to hampering many markets globally. Even pharmaceutical companies were focusing on developing vaccines and drugs for COVID-19. All resources were being utilized for battling the pandemic. This had a negative impact on the growth pf the global atrophic vaginitis treatment market. However, in the post-pandemic era there has been an increase in awareness among people regarding their health and well-being. This is estimated to boosts growth of the market.
Key Takeaways:
The global Atrophic Vaginitis Treatment Market is expected to witness robust growth, exhibiting CAGR of 7.5 % over the forecast period, due to growing acquisitions by key players. For instance, a first-of-its-kind diabetes treatment medicine was launched by Novo Nordisk India in 2022. The firm launched the world's earliest and only oral semaglutide.
Asia-Pacific is anticipated to witness robust growth in the global vaginitis treatment market during the forecast period, due to growing initiatives by the government and increasing incidences of vaginal infection in women.
Key players active in the global vaginitis treatment market are Novartis, Merck & Co., Inc., Lumavita AG, AstraZeneca, Eli Lilly and Company, TherapeuticsMD Inc., Allergan, Janssen Pharmaceuticals Inc., AbbVie Inc., Mylan N.V, TherapeuticsMD, Inc., Hikma Pharmaceuticals plc, Ligand Pharmaceuticals Incorporated, AbbVie Inc., Upsher-Smith Laboratories, LLC, Bristol-Myers Squibb Company, Pfizer Inc, Melinta Therapeutics, Inc, GSK plc., Perrigo Company plc, and Lupin.
Comments
Post a Comment